Please login to the form below

Not currently logged in
Email:
Password:

MyoKardia

This page shows the latest MyoKardia news and features for those working in and with pharma, biotech and healthcare.

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Other partnerships in Sanofi's Sunrise initiative include a $200m cardiomyopathy project with MyoKardia, and funding agreements with start-ups Warp Drive Bio - focusing on the use of genomics to discover

Latest news

  • Sanofi licenses cardiomyopathy programme in $200m deal Sanofi licenses cardiomyopathy programme in $200m deal

    MyoKardia's approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of the disease. ... The deal with MyoKardia has been set up under Sanofi's Sunrise initiative, which focuses on

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2014 Pharma deals during September 2014

    One can't escape one's past. Another creative deal also with a US theme is the early stage deal between MyoKardia, a company based in California, and Sanofi. Myokardia will ... That may still be on the cards as Sanofi has made an equity investment in

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    209. MyoKardia/ Sanofi. Licence and collaboration. 5. Three programmes for treatment of genetic forms of cardiomyopathy.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    California, US-based MyoKardia has appointed Dr June Lee as chief operating officer and Dr Radhika Tripuraneni as vice president of medical affairs. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    Will lead programme to target genetic heart disease. MyoKardia has appointed former VP, clinical development at AstraZeneca Jonathan Fox to chief medical officer. ... Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics